Filana Therapeutics (FLNA) Net Income (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Net Income of -$9.6 million for Q2 2026, up 79.02% year-over-year from -$5.3 million in Q2 2025, and up 15.98% quarter-over-quarter from -$11.4 million in Q1 2026.
Filana Therapeutics (FLNA) Net Income (2010 - 2026) Analysis & Trends
Filana Therapeutics' Net Income history runs 17 years deep, the most recent figure standing at -$9.6 million for Q2 2026.
- In Q2 2026, Net Income rose 79.02% year-over-year to -$9.6 million; the TTM figure through Jun 2026 stood at -$46.7 million (up 64.3% YoY), while the FY2025 annual figure was -$207.3 million, up 12.95% from the prior year.
- Net Income for Q2 2026 stood at -$9.6 million, up from -$11.4 million in the prior quarter.
- The five-year high for Net Income was -$9.6 million in Q2 2026, with the low at -$61.6 million in Q2 2024.
- The 5-year median for Net Income is -$22.0 million (2022), against an average of -$24.5 million.
- The sharpest annual moves came in 2022 and 2026: Net Income slumped 371.72% in 2022, then surged 79.02% in 2026.
- Filana Therapeutics' Net Income stood at -$19.8 million in 2022, then retreated by 16.5% to -$23.1 million in 2023, then fell by 28.39% to -$29.6 million in 2024, then jumped by 53.83% to -$13.7 million in 2025, then surged by 30.16% to -$9.6 million in 2026.
- Business Quant data shows FLNA's Net Income at -$9.6 million in Q2 2026, -$11.4 million in Q1 2026, and -$13.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Filana Therapeutics | 45.29 Mn | 45.29 Mn | - | -8.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.56 Mn |
| Mar 31, 2026 | -11.37 Mn |
| Dec 31, 2025 | -13.68 Mn |
| Sep 30, 2025 | -12.09 Mn |
| Jun 30, 2025 | -45.55 Mn |
| Mar 31, 2025 | -24.80 Mn |
| Dec 31, 2024 | -29.64 Mn |
| Sep 30, 2024 | -30.85 Mn |
| Jun 30, 2024 | -61.62 Mn |
| Mar 31, 2024 | -20.18 Mn |
| Dec 31, 2023 | -23.08 Mn |
| Sep 30, 2023 | -28.24 Mn |
| Jun 30, 2023 | -26.94 Mn |
| Mar 31, 2023 | -24.83 Mn |
| Dec 31, 2022 | -19.81 Mn |
| Sep 30, 2022 | -20.88 Mn |
| Jun 30, 2022 | -19.91 Mn |
| Mar 31, 2022 | -18.10 Mn |
| Dec 31, 2021 | -14.47 Mn |
| Sep 30, 2021 | -9.78 Mn |